Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Report 2026

Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview

• Calcitonin Gene-Related Peptide (CGRP) Inhibitors market size has reached to $3.14 billion in 2025 • Expected to grow to $5.02 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: Increasing Prevalence Of Migraine Fueling The Growth Of The Market Due To Increasing Stress Levels And Improved Treatment Options • Market Trend: Innovations And FDA Approvals Drive Growth In The Market For Migraine Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

Calcitonin gene-related peptide (CGRP) inhibitors are a class of drugs that block the activity of the calcitonin gene-related peptide (CGRP) pathway, which is involved in transmitting pain and dilating blood vessels in the brain. These inhibitors help reduce the frequency and severity of migraines and are used as a treatment option in patients with chronic or episodic migraines. The main types of inhibitors in the calcitonin gene-related peptide (CGRP) inhibitors are monoclonal antibodies, small molecules and peptides. Monoclonal antibodies refer to laboratory-produced molecules that are designed to bind specifically to a single target, such as a protein or receptor in the body. The mechanisms of action include anti-CGRP ligand therapies and CGRP receptor antagonists. Routes of administration vary and include oral, nasal, and intravenous delivery. Treatment types are categorized into preventive and acute migraine therapies. End users comprise hospitals, specialty clinics, mail-order pharmacies, and retail pharmacies.

What Is The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Growth Forecast?

The calcitonin gene-related peptide (cgrp) inhibitors market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to expanding chronic migraine patient pool, pipeline expansion of oral CGRP inhibitors, increasing demand for long-term migraine prevention, improved patient adherence to targeted therapies, growing access in emerging markets. Major trends in the forecast period include growing adoption of targeted migraine therapies, increasing shift toward preventive migraine treatment, rising preference for non-opioid pain management, expansion of oral CGRP small molecule inhibitors, increasing awareness and diagnosis of chronic migraine.

Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Segmentation

1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides 2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist 3) By Route of Administration: Oral, Nasal, Intravenous 4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment 5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies Subsegments: 1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality) 2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant 3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems

What Is The Driver Of The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

The increasing prevalence of migraine is expected to propel the growth of the calcitonin gene-related peptide (CGRP) inhibitors market going forward. A migraine is an intense headache that can cause throbbing pain, often on one side of the head. It is usually accompanied by nausea, vomiting, and sensitivity to light and sound. The increasing prevalence of migraine is due to rising stress levels, as chronic stress activates neural pathways. Calcitonin gene-related peptide (CGRP) inhibitors help in migraine management by offering a targeted, preventative mechanism and compatibility with both acute and chronic care regimens. They reduce headache frequency and severity through efficient CGRP receptor blockade, improving patient well-being and daily functioning. For instance, in January 2023, according to the report by the National Library of Medicine, a US-based health information institution, the global prevalence of migraine is between 14% and 15%, contributing to 4.9% of the global disease burden. Therefore, the increasing prevalence of migraine is driving the growth of the calcitonin gene-related peptide (CGRP) inhibitors industry.

Key Players In The Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

Major companies operating in the calcitonin gene-related peptide (cgrp) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.

Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Trends and Insights

Major companies operating in the calcitonin gene-related peptide (CGRP) inhibitors market are focusing on developing innovative products for getting approvals, such as calcitonin gene-related peptide (CGRP) receptor antagonists to enhance migraine treatment efficacy, expanding therapeutic indications, and offering more convenient administration routes such as oral and intranasal formulations. Calcitonin gene-related peptide (CGRP) receptor antagonist is a drug that inhibits the calcitonin gene-related peptide (CGRP) receptor to block migraine-related pain signaling. For instance, in April 2023, AbbVie Inc., a US-based biotech company, received approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) to treat chronic migraine in adults. QULIPTA is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that works by blocking calcitonin gene-related peptide (CGRP) receptors, which are involved in migraine pathophysiology, thereby helping to prevent migraine attacks.

What Are Latest Mergers And Acquisitions In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

In August 2024, Organon, a US-based healthcare company focused on women’s health, expanded its commercialization agreement with Eli Lilly and Company to become the sole distributor and promoter of Emgality (galcanezumab) in 11 additional markets. With this agreement, Organon aims to strengthen its migraine treatment portfolio and extend global patient access by leveraging Lilly’s marketed therapy alongside Organon’s commercialization capabilities. Eli Lilly and Company is a US-based pharmaceutical and biotechnology company that develops and markets Emgality, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP) for the preventive treatment of migraine.

Regional Insights

North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

The calcitonin gene-related peptide (CGRP) inhibitors market consists of sales of aimovig, emgality, ubrogepant, rimegepant, atogepant, and ajovy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Report 2026?

The calcitonin gene-related peptide (cgrp) inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin gene-related peptide (cgrp) inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.